CPA
ANIP icon

Capital Performance Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Capital Performance Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10
Closed -$597 – 311
2024
Q3 		$597 Buy
+10
New +$610 ﹤0.01% 2166

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Capital Performance Advisors's ANIP Position: Q4 2024 in Review

Capital Performance Advisors sold out of ANI Pharmaceuticals (ANIP) in Q4 2024, closing a stake of 10 shares — an estimated $597 sold.

Capital Performance Advisors first reported a position in ANIP in Q3 2024 and held it in 1 quarter. The position peaked at $597 in Q3 2024. 205 funds tracked by Wall St. Rank hold ANIP as of Q4 2024.

  • Capital Performance Advisors reported no remaining ANI Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 10 ANI Pharmaceuticals shares in Q4 2024, an estimated $597.
  • Capital Performance Advisors first reported a position in ANI Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's ANI Pharmaceuticals position peaked at $597 in Q3 2024.
  • 205 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.